An integrated mammalian library approach for optimization and enhanced microfluidics-assisted antibody hit discovery
Source abstract
Abstract
Recent years have seen the development of a variety of mammalian library approaches for display and secretion mode. Advantages include library approaches for engineering, preservation of precious immune repertoires and their repeated interrogation, as well as screening in final therapeutic format and host. Mammalian display approaches for antibody optimization exploit these advantages, necessitating the generation of large libraries but in turn enabling early screening for both manufacturability and target specificity. For suitable libraries, high antibody integration rates and resulting monoclonality need to be balanced - we present a solution for sufficient transmutability and acceptable monoclonality by applying an optimized ratio of coding to non-coding lentivirus. The recent advent of microfluidic-assisted hit discovery represents a perfect match to mammalian libraries in secretion mode, as the lower throughput fits well with the facile generation of libraries comprising a few million functional clones. In the presented work, Chinese Hamster Ovary cells were engineered to both express the target of interest and secrete antibodies in relevant formats, and specific clones were strongly enriched by high throughput screening for autocrine cellular binding. The powerful combination of mammalian secretion libraries and microfluidics-assisted hit discovery could reduce attrition rates and increase the probability to identify the best possible therapeutic antibody hits faster.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Viral Infectious Diseases and Gene Expression in Insects · Monoclonal and Polyclonal Antibodies Research · CRISPR and Genetic Engineering
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Protein Engineering and Antibody Technologies, Merck KGaA, Darmstadt, Germany
Discovery Biology, Syngene International, Phase-IV, Bangalore, India
Protein Engineering and Antibody Technologies, EMD Serono, Billerica, MA, USA
References (53)
Show source-provided references
1. 10.1080/19420862.2016.121214910.1080/19420862.2016.1212149 ↗
2. Krah S · Methods in Molecular Biology · 2018 · 1827 · 14510.1007/978-1-4939-8648-4_8 ↗
3. 10.1038/nbt.405210.1038/nbt.4052 ↗
4. 10.1007/s12257-020-0093-710.1007/s12257-020-0093-7 ↗
5. Javanmardi K · 2021 · 81 · 5099
6. Wang Y · Sci Adv · 2021 · 7 · 383910.1126/sciadv.abe3839 ↗
7. Zhang H · Chem Biol · 2013 · 20 · 73410.1016/j.chembiol.2013.04.012 ↗
8. Nehlsen K · BMC Biotechnol · 2009 · 9 · 110.1186/1472-6750-9-100 ↗
9. 10.1002/bit.2696510.1002/bit.26965 ↗
10. Matreyek KA · Nucleic Acids Res · 2020 · 48 · 110.1093/nar/gkz1097 ↗
11. 10.1074/jbc.RA120.01505310.1074/jbc.RA120.015053 ↗
12. Smith ES · Curr Drug Discov Technol · 2014 · 11 · 4810.2174/157016381101140124163634 ↗
13. 10.1038/nrg368610.1038/nrg3686 ↗
14. 10.1080/19420862.2019.161867310.1080/19420862.2019.1618673 ↗
15. 10.1080/19420862.2019.166269110.1080/19420862.2019.1662691 ↗
16. 10.4161/mabs.2.5.1297010.4161/mabs.2.5.12970 ↗
17. Luo R · Sci Rep · 2020 · 10 · 110.1038/s41598-019-56847-4 ↗
18. Jia JY · Acta Pharmacol Sin · 2022 · 43 · 95410.1038/s41401-021-00707-3 ↗
19. Durrant MG · bioRxiv · 2021
20. 10.1080/19420862.2016.116099010.1080/19420862.2016.1160990 ↗
21. 10.1093/protein/gzy00410.1093/protein/gzy004 ↗
22. 10.1016/j.ymeth.2013.06.01010.1016/j.ymeth.2013.06.010 ↗
23. 10.1038/s41423-020-0440-910.1038/s41423-020-0440-9 ↗
24. Dyson MR · MAbs · 2020 · 12(1):1829335
25. Zhou Y · PLOS One · 2013 · 8 · 210.1371/annotation/b4828aa9-5156-499b-9f30-a8f9c9dd4f8e ↗
26. 10.1016/j.celrep.2018.01.07110.1016/j.celrep.2018.01.071 ↗
27. 10.1016/j.ymeth.2016.11.00610.1016/j.ymeth.2016.11.006 ↗
28. 10.1016/j.mam.2017.09.00410.1016/j.mam.2017.09.004 ↗
29. 10.1038/nprot.2013.04610.1038/nprot.2013.046 ↗
30. 10.1080/19420862.2019.162412610.1080/19420862.2019.1624126 ↗
31. Fitzgerald V · Anal Chem · 2015 · 87 · 99710.1021/ac503547j ↗
32. Jones BE · .
33. 10.1021/acschembio.6b0079410.1021/acschembio.6b00794 ↗
34. 10.1016/j.trac.2019.05.01810.1016/j.trac.2019.05.018 ↗
35. Yanakieva D · Sci Rep · 2020 · 10 · 110.1038/s41598-020-66927-5 ↗
36. 10.1039/C8LC00818C10.1039/C8LC00818C ↗
37. 10.1038/s41587-020-0466-710.1038/s41587-020-0466-7 ↗
38. Sadelain M · Nat Rev Cancer · 2011 · 12 · 5110.1038/nrc3179 ↗
39. 10.1073/pnas.161640811410.1073/pnas.1616408114 ↗
40. Josephides D · SLAS Technol · 2020 · 17710.1177/2472630319892571 ↗
41. 10.1038/nbt.397210.1038/nbt.3972 ↗
42. Kim S · Mol Cells · 2017 · 40 · 65510.14348/molcells.2017.0106 ↗
43. Erasmus MF · Commun Biol · 2021 · 4(1):350
44. Tanno H · Sci Adv · 2020 · 6(17):eaay9093
45. Nguyen AW · Methods Mol Biol · 2020 · 2070 · 39710.1007/978-1-4939-9853-1_22 ↗
46. Gaa R · MAbs · 2021 · 13 · 197813010.1080/19420862.2021.1978130 ↗
47. 10.1007/7651_2015_27010.1007/7651_2015_270 ↗
48. Han KH · FASEB J off Publ Fed Am Soc Exp Biol · 2016 · 30 · 738
49. Zheng T, Xie J, Yang Z, et al. Antibody selection using clonal cocultivation of Escherichia colieukaryotic cells in miniecosystems. Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6145-E6151.10.1073/pnas.1806718115 ↗
50. Robertson N, Lopez-Anton N, Gurjar SA, et al. Development of a novel mammalian display system for selection of antibodies against membrane proteins. J Biol Chem. 2020 Dec 25;295(52):18436–18448.10.1074/jbc.RA120.015053 ↗
51. 10.1002/btpr.230710.1002/btpr.2307 ↗
52. Turan S · Gene [Internet · 2013 · 515 · 110.1016/j.gene.2012.11.016 ↗
53. Yanakieva D · MAbs · 2022 · 14 · 201896010.1080/19420862.2021.2018960 ↗